AG真人官方

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in two upcoming investor conferences taking place in September:

• Event: 2025 Wells Fargo Healthcare Conference
  Location: Boston, MA
  Date/Time: Friday, September 5, 2025, at 11:00 am ET
  Format: Fireside Chat

• Event: H.C. Wainwright 27^th Annual Global Investment Conference
  Location: New York, NY
  Date/Time: Monday, September 8, 2025, at 7:00 am ET
  Format: Pre-Recorded On-Demand Presentation

A webcast of the fireside chat at the 2025 Wells Fargo Healthcare Conference will be available on the 鈥淓vents & Presentations鈥� section of the Company鈥檚 website at . Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit , and follow us on , , and .

View source version on businesswire.com:

Investor and Media Contact:

Gitanjali Jain

Senior Vice President, Investor Relations and External Affairs

Kezar Life Sciences, Inc.

[email protected]

Source: Kezar Life Sciences